Using real‐world data to evaluate the association of incretin‐based therapies with risk of acute pancreatitis: a meta‐analysis of 1 324 515 patients from observational studies
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Aim: To investigate the real‐world incidence of acute pancreatitis ( AP ) associated with incretin‐based therapy ( IBT ). Methods: We carried out a systematic review and meta‐analysis of observational studies using Medline, PubMed , Embase, the Cochrane Database, ClinicalTrials.gov and conference proceedings. We included: those studies in which AP was a pre‐defined clinical outcome; longitudinal studies (case–control, cohort); studies that adjusted for confounders; studies that reported on a population exposed to IBT ; studies in which non‐ IBT users or past users (who received IBTs >90 days before the index date) were used as the control group; studies that reported risk estimates [relative risks, odds ratios ( ORs ) or hazard ratios] with 95% confidence intervals ( CIs ) for AP event with IBT use, or that reported sufficient data to estimate these; and publications in the English language. Data were extracted by two independent investigators, and a consensus was reached with involvement of a third. Study‐specific ORs from seven cohort studies and two case–control studies were meta‐analysed using random‐effects models. Associations were tested in subgroups representing different patient characteristics and study quality. Results: A total of nine studies that included 1 324 515 patients and 5195 cases of AP were included in our meta‐analysis. The summary estimate of OR for an association between IBT and AP was 1.03 (95% CI 0.87–1.20). Conclusions: The present meta‐analysis of real‐world data does not suggest that IBT is associated with AP . Although we should continue to remain vigilant, IBTs should be regarded as reasonable options to consider adding to the regimen of a patient with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Meta-analysis Spurious precision? Meta-analysis of observational studies
Egger, M., Schneider, M., & Smith, G. D. (1998) · BMJ · doi:10.1136/bmj.316.7125.140 · Cited by 997
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“[4], examined the FDA Adverse Event Reporting System database and found a positive association between IBT use (exenatide and sitagliptin) and pancreatitis; however, the FDA database is limited by possible ascertainment bias, which undermines its external validity, a lack of known duration of drug exposure or presence…”
BackgroundSystematic review and meta-analysis of psychological therapies for children with chronic pain
Fisher, E., Heathcote, L., Palermo, T. M., de C Williams, A. C., Lau, J., & Eccleston, C. (2014) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsu008 · Cited by 710
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467 · cited 6×
“Selection Comparabilitya Outcome Total score Source 1 2 3 4 5A 5B 6 7b 8c Dore† 2009 [23] * * * * * * * * * 9 Dore† 2011 [24] * * * * * * * * * 9 Garg† 2010 [25] * * * * * * * 7 Romley† 2012 [26] * * * * * * * * * 9 Seong† 2013 [29] * * * * * * 6 Funch† 2014 [30] * * * * * * * * * 9 Fallie† 2014 [31] * * * * * * * * *…”
BackgroundMethodResultInfluentialLi, L., Shen, J., Bala, M. M., Busse, J. W., Ebrahim, S., Vandvik, P. O., Rios, L. P., Malaga, G., Wong, E., Sohani, Z., et al. (2014) · BMJ · doi:10.1136/bmj.g2366 · Cited by 254
Systematic reviews of adverse effects: framework for a structured approach
Loke, Y. K., Price, D., Herxheimer, A., & the Cochrane Adverse Effects Methods Group (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-32 · Cited by 253
Alves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186
Exenatide (Exendin-4)–Induced Pancreatitis
Denker, P. S., & Dimarco, P. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-2043 · Cited by 140
Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.010 · Cited by 106
Cited by
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394
Monami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12926 · Cited by 243
Storgaard, H., Cold, F., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12885 · Cited by 155
Metadata
- Authors
- Wang, T., Wang, F., Gou, Z., Tang, H., Li, C., Shi, L., & Zhai, S.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-10-06
- Volume
- 17
- Issue
- 1
- Pages
- 32-41
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2058350670
- Cited by
- 62
- References
- 14
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.